title: Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.
abstract: Immunotherapy has the potential to improve clinical outcomes with little toxicity for pediatric patients with brain tumors. We conducted a pilot feasibility study of tumor lysate-pulsed dendritic cell (DC) vaccination in pediatric patients (1 to 18 years old) with newly diagnosed or recurrent high-grade glioma (HGG). A total of nine DC vaccine doses, each containing 1 × 10(6) cells per dose were administered to three out of the seven originally enrolled patients. Toxicities were limited to mild side-effects, except in one case of elevated alkaline phosphatase, which resolved without clinical consequences. Two patients with primary lesions amongst the three vaccinated were alive at the time of writing, both without evidence of disease. Pre- and post-vaccination tumor samples from a patient with an anaplastic oligoastrocytoma that recurred failed to demonstrate immune cell infiltration by immunohistochemistry. Peripheral cytokine levels were evaluated in one patient following DC vaccination and demonstrated some changes in relation to vaccination. DC vaccine is tolerable and feasible with some limitations for pediatric patients with HGG. Dendritic cell based immunotherapy may provide some clinical benefit in pediatric patients with glioma, especially for patients with minimal residual disease, but further investigation of this modality is required.
authors: Department of Pediatrics, Division of Pediatric Hematology/ Oncology, Harbor-UCLA Medical Center/LA Biomed, David Geffen School of Medicine UCLA, Torrance, CA 90502, USA. jlasky@labiomed.org
authors: Joseph L
authors: JL
authors: Lasky
authors: Eduard H
authors: EH
authors: Panosyan
authors: Ashley
authors: A
authors: Plant
authors: Tom
authors: T
authors: Davidson
authors: William H
authors: WH
authors: Yong
authors: Robert M
authors: RM
authors: Prins
authors: Linda M
authors: LM
authors: Liau
authors: Theodore B
authors: TB
authors: Moore
mesh_terms: D000293:Adolescent; D001932:Brain Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D005240:Feasibility Studies; D005260:Female; D005910:Glioma / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007124:Immunoenzyme Techniques; D007167:Immunotherapy; D007223:Infant; D007937:Leukapheresis; D008297:Male; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D010865:Pilot Projects
chemical_list: D019496:Cancer Vaccines; D016207:Cytokines
keywords: Pediatric neuro-oncology; dendritic cell vaccine; high grade glioma; immunotherapy
references: Neurosurg Clin N Am. 2010 Jan;21(1):139-57
references: 19944973
references: Pediatr Blood Cancer. 2010 Apr;54(4):519-25
references: 19852061
references: Neurotherapeutics. 2009 Jul;6(3):570-86
references: 19560746
references: Nat Immunol. 2007 Sep;8(9):967-74
references: 17581537
references: Clin Cancer Res. 2005 Aug 1;11(15):5515-25
references: 16061868
references: Cancer Immunol Immunother. 2007 Sep;56(9):1485-99
references: 17285289
references: Lancet Oncol. 2006 Mar;7(3):241-8
references: 16510333
references: J Clin Oncol. 2007 Jun 20;25(18):2546-53
references: 17577033
references: Cancer Gene Ther. 2009 May;16(5):430-8
references: 19096444
references: Recent Results Cancer Res. 2009;171:105-24
references: 19322540
references: Childs Nerv Syst. 2010 Dec;26(12):1785-93
references: 20668863
references: Nat Rev Clin Oncol. 2011 May 24;8(9):551-61
references: 21606971
references: Clin Cancer Res. 2011 Mar 15;17(6):1603-15
references: 21135147
references: Radiat Res. 2010 Dec;174(6):840-50
references: 21128808
references: Blood. 2002 Jul 1;100(1):174-7
references: 12070024
references: Cancer Immunol Immunother. 2005 Aug;54(8):721-8
references: 16010587
references: J Immunother. 2010 Jan;33(1):1-7
references: 19952961
references: J Neurosurg Pediatr. 2010 Aug;6(2):145-9
references: 20672935
references: Clin Cancer Res. 2009 Nov 1;15(21):6503-10
references: 19843660
references: Semin Radiat Oncol. 2010 Jan;20(1):58-66
references: 19959032
references: J Hum Genet. 2001;46(5):267-72
references: 11355017
references: J Neurooncol. 2012 May;108(1):1-10
references: 22173741
references: N Engl J Med. 2010 Sep 30;363(14):1324-34
references: 20879881
references: Curr Neurol Neurosci Rep. 2010 Jul;10(4):259-66
references: 20424975
references: Neuro Oncol. 2011 Feb;13(2):223-34
references: 21177781
references: Neuro Oncol. 2011 Jan;13(1):109-18
references: 20974795
references: Neurology. 2004 Apr 27;62(8):1311-6
references: 15111667
references: Neuro Oncol. 2004 Jul;6(3):236-46
references: 15279716